Journal
CANCER LETTERS
Volume 305, Issue 1, Pages 8-20Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.02.012
Keywords
Mesenchymal stem cells; Cancer; Cytotherapy; Gene therapy
Categories
Funding
- Juvenile Diabetes Foundation
- VGH & UBC Hospital Foundation
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) are the first type of stem cells to be utilized in clinical regenerative medicine, mainly owing to their capacity for multipotent differentiation and the feasibility of autologous transplantation. More recently, the specific tumor-oriented migration and incorporation of MSCs have been demonstrated in various pre-clinical models, highlighting the potential for MSCs to be used as an ideal carrier for anticancer gene delivery. Engineered with specific anticancer genes, MSCs possess the ability of dual-targeting tumor cells. This contrasts with non-engineered native MSCs which have intrinsic pro- and anti-tumorigenic properties. Engineered MSCs are capable of producing specific anticancer agents locally and constantly. Astute investigation on engineered MSCs may lead to a new avenue toward an efficient therapy for patients with cancer. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available